Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

which has no proven cardiovascular benefits and is used infrequently due to side effects. In STRIDE, published simultaneously in The Lancet, the functional benefit of injectable semaglutide was ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Oral semaglutide reduced major cardiovascular events ... “On the concerning side, it's a very diverse population that we take care of, and I believe that we need more studies that included ...